MRI indicates magnetic resonance imaging; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial; WML, white matter lesion.
aOther reasons for unwillingness to participate include participant could not lie flat for extended period (n = 7), participant reported metal in body before formal screening (n = 8), participant concerns about stent or other cardiac device (n = 8), concerns about body size (n = 2), other reasons (n = 7), and unknown reason (n = 22).
bOther reasons for ineligibility include participant concerns about stent or other cardiac device (n = 8), use of pain pump (n = 2), prolonged hospitalization (n = 2), participant declined consent (n = 2), participant too large for MRI scanner (n = 1), and other reasons (n = 7).
Estimates denote the estimated change for transformed white matter lesion (WML) volume at 1452 days (3.98 years) among participants with WML measurement at baseline and follow-up, based on a linear mixed model, adjusting for intracranial volume and days since randomization, with random effects for participant and magnetic resonance imaging facility. Negative values denote decreases from baseline; positive values, increases from baseline. Differences represent intensive treatment group minus standard treatment group. WML volumes were transformed using inverse hyperbolic sine transformation, f(x) = log(x + (x2 + 1)0.5). BP indicates blood pressure; CVD, cardiovascular disease; SE, standard error.
Estimates denote the estimated change in total brain volume at 1452 days (3.98 years) among participants with WML measurement at baseline and follow-up, based on a linear mixed model, adjusting for intracranial volume and days since randomization, with random effects for participant and magnetic resonance imaging facility. Differences represent intensive treatment group minus standard treatment group. BP indicates blood pressure; CVD, cardiovascular disease; SE, standard error.
eMethods. Multiple Imputation and Inverse Probability Weighting to Assess the Influence of Selection Into the Magnetic Resonance Imaging (MRI) Substudy and Missing Follow-up MRI Scans
eTable 1. Additional Baseline Characteristics of Participants With a Measured White Matter Lesion Volume From the Baseline Magnetic Resonance Imaging Scan, by Treatment Group
eTable 2. Baseline Characteristics of Participants in the MRI Substudy Versus Remaining Trial Participants
eTable 3. Baseline Characteristics of Participants in the MRI Substudy With and Without a Follow-up MRI With Measured White Matter Lesion Volume
eTable 4. Changes in Small Vessel Ischemic Disease Lesion Volume by Treatment Group
eTable 5. Sensitivity Analyses for Magnetic Structural Outcomes Based on Inverse Probability Weighting and Multiple Imputation
eTable 6. Association of Change in Structural Magnetic Resonance Imaging Outcomes by Adjudicated Cognitive Status
eFigure 1. Eligibility, Randomization, and Follow-up for Participants in the MRI Substudy for the Secondary Outcome of Total Brain Volume
eFigure 2. Mean Systolic Blood Pressure by Treatment Group for Participants in MRI Substudy
eFigure 3. Association Between Change in White Matter Lesion Volume and Adjudicated Cognitive Status
eFigure 4. Association Between Change in Total Brain Volume and Adjudicated Cognitive Status
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
The SPRINT MIND Investigators for the SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019;322(6):524–534. doi:10.1001/jama.2019.10551
Is intensive blood pressure treatment associated with less progression of small vessel ischemic disease, as reflected by cerebral white matter lesion volume?
In this substudy of a randomized clinical trial of 449 hypertensive patients with longitudinal brain magnetic resonance imaging, intensive blood pressure management to a target of less than 120 mm Hg, vs less than 140 mm Hg, was associated with a smaller increase in white matter lesion volume (0.92 cm3 vs 1.45 cm3).
More intensive blood pressure management was associated with less progression of cerebral small vessel ischemic disease, although the difference was small.
The effect of intensive blood pressure lowering on brain health remains uncertain.
To evaluate the association of intensive blood pressure treatment with cerebral white matter lesion and brain volumes.
Design, Setting, and Participants
A substudy of a multicenter randomized clinical trial of hypertensive adults 50 years or older without a history of diabetes or stroke at 27 sites in the United States. Randomization began on November 8, 2010. The overall trial was stopped early because of benefit for its primary outcome (a composite of cardiovascular events) and all-cause mortality on August 20, 2015. Brain magnetic resonance imaging (MRI) was performed on a subset of participants at baseline (n = 670) and at 4 years of follow-up (n = 449); final follow-up date was July 1, 2016.
Participants were randomized to a systolic blood pressure (SBP) goal of either less than 120 mm Hg (intensive treatment, n = 355) or less than 140 mm Hg (standard treatment, n = 315).
Main Outcomes and Measures
The primary outcome was change in total white matter lesion volume from baseline. Change in total brain volume was a secondary outcome.
Among 670 recruited patients who had baseline MRI (mean age, 67.3 [SD, 8.2] years; 40.4% women), 449 (67.0%) completed the follow-up MRI at a median of 3.97 years after randomization, after a median intervention period of 3.40 years. In the intensive treatment group, based on a robust linear mixed model, mean white matter lesion volume increased from 4.57 to 5.49 cm3 (difference, 0.92 cm3 [95% CI, 0.69 to 1.14]) vs an increase from 4.40 to 5.85 cm3 (difference, 1.45 cm3 [95% CI, 1.21 to 1.70]) in the standard treatment group (between-group difference in change, −0.54 cm3 [95% CI, −0.87 to −0.20]). Mean total brain volume decreased from 1134.5 to 1104.0 cm3 (difference, −30.6 cm3 [95% CI, −32.3 to −28.8]) in the intensive treatment group vs a decrease from 1134.0 to 1107.1 cm3 (difference, −26.9 cm3 [95% CI, 24.8 to 28.8]) in the standard treatment group (between-group difference in change, −3.7 cm3 [95% CI, −6.3 to −1.1]).
Conclusions and Relevance
Among hypertensive adults, targeting an SBP of less than 120 mm Hg, compared with less than 140 mm Hg, was significantly associated with a smaller increase in cerebral white matter lesion volume and a greater decrease in total brain volume, although the differences were small.
ClinicalTrials.gov Identifier: NCT01206062
In older adults at risk of vascular disease, the effect of intensive systolic blood pressure (SBP) control on brain heath is uncertain, despite its proven efficacy for reducing cardiovascular disease morbidity and mortality.1 Epidemiologic data have identified hypertension as a primary risk factor for cerebral small vessel ischemic disease (SVID), particularly development of white matter lesions (WMLs).2,3 Observational studies have increasingly suggested that SVID is associated with cognitive decline and the pathogenesis of Alzheimer disease and related dementias.4,5 WMLs seen on brain magnetic resonance imaging (MRI) are an independent risk factor for cognitive decline and dementia.6,7 It has been estimated that 30% to 60% of patients with Alzheimer disease and related dementias have vascular findings contributing to their cognitive impairment, while Alzheimer disease pathology may be present in 40% to 80% of patients with dementia for which the primary etiology is classified as vascular.8-10
There is limited evidence supporting a beneficial effect of antihypertensive treatment in slowing the progression of SVID in the brain.11 To the contrary, some hypothesize that intensive SBP control may adversely affect the brain through mechanisms such as decreasing cerebral perfusion.12 The Systolic Blood Pressure Intervention Trial (SPRINT) tested the effect of intensive SBP control (SBP target <120 mm Hg) vs a standard SBP treatment goal of less than 140 mm Hg. Cognitive results from that trial indicated a lower rate of mild cognitive impairment with intensive SBP control, with an inconclusive effect on probable dementia.13 Brain MRI scans were obtained in a subgroup of participants to test the primary hypothesis that the increase in WML volume, a measure of SVID progression, would be lower in participants randomized to intensive SBP control. The secondary hypothesis was that declines in total brain volume (TBV) would be less in the intensive treatment group.
The overall trial design and primary outcome results have been described,1,14 and the study protocol is provided in Supplement 1. The trial and MRI substudy were approved by the institutional review board at each participating site, and each participant provided written informed consent.
Briefly, participants were 50 years or older with SBP between 130 and 180 mm Hg at the screening visit and had increased cardiovascular risk. Participants were considered to have increased cardiovascular risk if they had clinical or subclinical cardiovascular disease, chronic kidney disease (defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m2), a 10-year Framingham cardiovascular disease risk of 15% or greater, or were 75 years or older. Individuals residing in a nursing home, persons with a diagnosis of dementia (based on medical record review), or those treated with medications primarily used for dementia therapy were excluded, as were persons with prevalent diabetes mellitus or a history of stroke. Between November 2010 and March 2013, a total of 9361 participants were randomized by the data coordinating center in a 1:1 allocation to an intensive treatment strategy with an SBP goal of less than 120 mm Hg or a standard treatment strategy with an SBP goal of less than 140 mm Hg. The algorithms and formulary for hypertension treatment are listed in the study protocol (Supplement 1).
A subset of participants (n = 2913) were recruited into a substudy to more extensively evaluate the effects of intensive SBP control on specific domains of cognitive function, the results of which are not presented here. MRI scans were obtained in a further subset of these participants to evaluate brain structure. All participants accessible to 1 of 7 designated MRI sites (27 clinic sites) were screened for the MRI substudy, and eligible participants provided written informed consent. Exclusion criteria for the MRI substudy included presence of a pacemaker, defibrillator, neurostimulator or other implanted electrical device, ferro-magnetic or unknown cerebral aneurysm clip, cochlear or other otologic implant, unknown metallic foreign bodies or exposure to metal fragments in or around the eyes, or severe claustrophobia.
Baseline measures, including age, sex, prior cardiovascular disease, and education, were collected via self-report; participants brought their antihypertensive medications to the baseline visit, where the medications were recorded. Race and ethnicity were collected via self-report using fixed categories to satisfy the National Institutes of Health Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research. Blood pressure was measured via standardized techniques as follows.15
All sites were provided with the Professional Digital Blood Pressure Monitor (Omron Healthcare; model 907XL) for BP measurement. Training in BP measurement technique emphasized proper positioning of participants, measurement of arm circumference and use of a proper cuff size, and the importance of a 5-minute rest period before obtaining the 3 seated automated BP values. During the rest and BP measurement periods, the protocol called for the participant to not be completing questionnaires, talking, or texting. Visit BP was the mean of 3 readings. A central laboratory, located in Minneapolis, Minnesota, analyzed all blood and urine samples.
MRIs were planned at baseline and 48 months after randomization. Several different MRI scanner models were used: 3T Phillips Achieva 3.2 (University of Alabama at Birmingham, Boston University, and Vanderbilt University), 3T Siemens Skyra VD11B (Wake Forest University), 3T Siemens Tim Trio VB17 (University of Miami and University of Pennsylvania), and 3T Siemens Verio VB17 (Case Western Reserve University).
Structural MRI of the brain included 1-mm isotropic T1, T2, and fluid-attenuated inversion recovery (FLAIR) imaging. Imaging parameters were as follows: T1 (repetition time = 1900 ms, echo time = 2.89 ms, field of view = 250 mm, thickness = 1 mm, slices = 176, native resolution = 1 mm isotropic), T2 (repetition time = 3200 ms, echo time = 409 ms, field of view = 250 mm, thickness = 1 mm, slices = 176, native resolution = 1 mm isotropic), and FLAIR (repetition time = 6000 ms, inversion time = 2200 ms, echo time = 285 ms, field of view = 258 mm, thickness = 1 mm, slices = 160, native resolution = 1 mm isotropic).
Scanner performance was monitored with quarterly Alzheimer Disease Neuroimaging Initiative and Function Biomedical Informatics Research Network phantom acquisition, with all scanners showing stability of phantom measurements throughout the trial.
Image processing was performed by the Center for Biomedical Image Computing and Analytics in the Department of Radiology at the University of Pennsylvania. All image analysts were blinded to treatment group. An automated pipeline was applied for preprocessing structural MRI scans, including correction of inhomogeneity16 and extraction of the intracranial tissues using multiatlas skull stripping.17 Anatomical regions of interest were identified using a multiatlas label fusion method18 and used to segment supratentorial gray matter and white matter tissues, with the sum of gray matter and white matter defining TBV. WMLs were identified from inhomogeneity-corrected and coregistered FLAIR and T1-weighted images using a deep learning–based segmentation method built on the UNet architecture,19 with the convolutional layers in the network replaced by an Inception ResNet architecture.20 The model was trained using a separate training set with human-validated segmentation of WML. WML segmentations were quality inspected by a neuroradiologist blinded to treatment group.
Thirteen participants with baseline scans showing structural brain lesions (large areas of encephalomalacia , tumors , subdural hematoma , prior brain resection ) and 3 patients who developed large strokes (2) or a subdural hematoma at follow-up were excluded from analyses.
On August 20, 2015, the director of the National Heart, Lung, and Blood Institute accepted a recommendation from the data and safety monitoring board to inform the investigators and participants of the cardiovascular outcome results and initiated the process to end the trial intervention. Because of this, the majority of follow-up MRI scans with a WML volume passing quality control (n = 428, 95.3%) occurred during a closeout period (from August 20, 2015, to July 1, 2016), when participants were either having, or transitioning to having, their BP managed by their primary care clinician, although antihypertensive medications were still being provided by the study. The median time between August 20, 2015, and the follow-up MRI scan for those conducted after August 20, 2015, was 196 days (interquartile range, 145-244 days). Adverse events during the intervention phase of the trial have been published.1,21,22
Methods for neuropsychological testing of cognitive status and adjudication have been described13 and are also described in the trial protocol (Supplement 1). For this report, cognitive assessments were only included through the trial closeout period (through July 1, 2016), as this corresponds to the timing of the follow-up MRI scans.
The trial protocol originally defined the primary MRI outcome as change in total SVID lesion volume, which encompasses lesions in the white matter, gray matter, and basal ganglia. Before any data analyses, the primary outcome was modified to consist solely of change in WML volume. This was done because WML volume is a more standard measurement of SVID and because the automated segmentation algorithm used in this trial was specifically trained to detect WMLs. Change in TBV was a secondary outcome.
Prespecified subgroups included age (<75 years vs ≥75 years), sex, race (nonblack vs black), chronic kidney disease (estimated glomerular filtration rate <60 vs ≥60 mL/min/1.73 m2), history of cardiovascular disease, baseline tertiles of SBP (≤129, 129 to <143, ≥143 mm Hg), and orthostatic hypotension.
Based on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the standard deviations for change in WML volume and TBV (40 months after randomization) were 2.77 cm3 and 16.45 cm3, adjusted for baseline values and intracranial volume.23 With 640 participants (320 participants in each treatment group), assuming 3% loss to follow-up per year, and a 2-sided significance level of .05, we estimated that we would be able to detect group differences over 4 years of 0.65 cm3 (WML volume) and 3.9 cm3 (TBV) with 80% power and of 0.76 cm3 (WML volume) and 4.5 cm3 (TBV) with 90% power.
Because of the skewed distribution for WML volume, we first applied an inverse hyperbolic sine transformation (asinh), which is similar to a log transformation but can accommodate values of zero.24 Linear mixed models, including random effects for participant and MRI facility, were used to estimate the change in WML volume and TBV between the treatment groups, including time since randomization (in days) and intracranial volume as covariates. Because the inverse hyperbolic sine transformation is nonlinear, and given the context of a mixed-effects model, back-transformation to the original scale of cm3 is difficult. Therefore, we also present estimates for WML volume based on a robust linear mixed model to aid in interpretation.25 Intuitively, this approach down-weights observations with large residuals or random effects, reducing their influence on model estimates. However, all formal hypothesis testing was based on the linear mixed models fit to transformed WML volumes. Interactions between treatment group and prespecified subgroups were assessed with a likelihood ratio test.
We also conducted 2 sets of sensitivity analyses. The first used inverse probability weighting and multiple imputation to examine the effect of selective entry into the MRI substudy and missing follow-up MRI scans (eMethods in Supplement 2). The second mimicked the primary analyses based on linear mixed models to examine the association between cognitive status during follow-up (no impairment, mild cognitive impairment, or probable dementia) with change in WML volume and TBV.
All analyses were performed using SAS version 9.4 (SAS Institute Inc) and R version 3.4.2 (R Project for Statistical Computing [http://www.r-project.org]). All hypothesis tests were 2-sided, and P values less than .05 were considered statistically significant. No adjustments for multiple comparisons were made, so the interpretation of secondary analyses should be considered exploratory.
Of the 1267 SPRINT participants screened for the MRI substudy, 998 were willing to participate, 793 were eligible, and 670 completed a baseline MRI scan with a measurement of WML volume that passed quality control (Figure 1). An analogous depiction for the secondary outcome of TBV is shown in eFigure 1 in Supplement 2. The major reasons for ineligibility included the presence of metal fragments (43.9%), claustrophobia (31.2%), or a pacemaker (8.8%).
Characteristics of the 670 participants who completed a baseline MRI scan did not differ between treatment groups (Table 1). At baseline, the mean age overall was 67.3 (SD, 8.2) years; 40.4% were women, and 33.1% were black. Mean SBP was 138.0 (SD, 16.6) mm Hg and mean diastolic BP was 77.8 (SD, 11.4) mm Hg. Additional baseline characteristics of participants are reported in eTable 1 in Supplement 2. Compared with participants not in the MRI substudy, those in the substudy were more likely to be women, black, and younger; had a lower SBP at baseline; and were less likely to have a history of cardiovascular disease (eTable 2 in Supplement 2). Participants in the MRI substudy also had higher scores on the Montreal Cognitive Assessment compared with the remaining participants in the trial.
There was a sustained between-group difference in SBP among participants in the MRI substudy. Mean SBP through the end of active intervention was 120.7 mm Hg in the intensive treatment group vs 134.9 mm Hg in the standard treatment group (difference, 14.2 mm Hg [95% CI, 13.1 to 15.3 mm Hg]) (eFigure 2 in Supplement 2). During the transitional closeout period from August 20, 2015, to July 1, 2016, mean SBPs increased slightly, to 122.1 for the intensive treatment group and 136.1 mm Hg for the standard treatment group, with only a small change to the SBP difference (14.0 mm Hg [95% CI, 9.3 to 18.8 mm Hg]) between groups.
Follow-up MRI scans were performed at a median of 3.97 years (range, 2.81-4.75 years) after randomization, after a median intervention period of 3.40 years (range, 2.46-4.30 years). Of the 670 participants with WML volume measurement at baseline, 462 completed the follow-up MRI (Figure 1). Image quality control requirements were not met for 13 participants with a follow-up MRI scan, resulting in a sample of 449 adults (249 in the intensive treatment group and 200 in the standard treatment group). The 221 participants who did not have a follow-up scan included 89 (13.3% of baseline population) who were unwilling to participate, 36 (5.4%) who were ineligible, 31 (4.6%) who withdrew from the trial or were lost to follow-up, 27 (4.0%) who died, and 25 (3.7%) for other reasons. Participants who did not have a follow-up MRI scan were more likely to be women, have a baseline history of cardiovascular disease, have higher SBP, have lower physical quality of life, and have lower baseline cognitive scores (eTable 3 in Supplement 2).
At the follow-up MRI assessment, the intensive treatment group had a significantly smaller increase in transformed WML volume compared with the standard treatment group. The mean transformed WML volume in the intensive treatment group increased from 1.99 asinh(cm3) at baseline to 2.14 asinh(cm3) at follow-up, while the standard treatment group increased from 1.96 to 2.25 asinh(cm3) (between-group difference, −0.13 asinh[cm3] [95% CI, −0.19 to −0.07]) (Table 2). Based on a robust linear mixed model, this approximately corresponds to a between-group difference for the change in WML volume of −0.54 cm3 (95% CI, −0.87 to −0.20 cm3) (Table 2).
Results were similar using whole brain output from the lesion segmentation algorithm, not restricted to supratentorial white matter (eTable 4 in Supplement 2). There was no evidence of subgroup heterogeneity with regard to the change in WML volume (P > .05 for interaction for all) (Figure 2). The intensive treatment group had a significantly greater decrease in TBV compared with the standard treatment group. In the intensive treatment group, mean TBV decreased from 1134.5 cm3 at baseline to 1104.0 cm3 at follow-up, compared with 1134.0 to 1107.1 cm3 in the standard treatment group. This represents a between-group difference in mean change for TBV of −3.7 cm3 (95% CI, −6.3 to −1.1).
In subgroup analyses for TBV, there was a significant interaction between treatment group and sex for the change in TBV (P = .04 for interaction) (Figure 3). Compared with women, who showed no difference for change in TBV by treatment group, men randomized to intensive treatment experienced greater declines in TBV compared with those in the standard treatment group.
Results of sensitivity analyses based on inverse probability weighting and multiple imputation to address 2 potential sources of bias—selective entry into the MRI substudy and missing follow-up MRI scans—are reported in eTable 4 in Supplement 2. Results for WML volume were generally unchanged, consistently indicating a smaller increase in WML volume for the intensive treatment group. In contrast, the between-group difference for change in TBV was somewhat attenuated and not statistically significant, decreasing from −3.7 cm3 (95% CI, −6.3 to −1.1) to −2.2 cm3 (95% CI, −6.5 to 2.2) (P = .32). There were a small number of participants in this imaging substudy who completed the follow-up MRI scan and were adjudicated as having mild cognitive impairment (n = 23) or probable dementia (n = 6). Participants with probable dementia did exhibit significantly larger increases in transformed WML volume as well as significantly larger decreases in TBV compared with participants adjudicated as having no cognitive impairment (eFigures 3 and 4 in Supplement 2).
In this imaging substudy of a randomized clinical trial, intensive SBP control was significantly associated with a smaller increase in mean WML volume compared with standard SBP control. There was also a significant association of intensive SBP control on the secondary outcome of TBV, with participants randomized to intensive treatment exhibiting larger mean declines in TBV. Given that the main structural correlate of hypertension on the brain is abnormal WML volumes, these results suggest that the development of this structural abnormality can be slowed by more intensive treatment of hypertension. However, the anatomical basis and functional significance of the greater brain volume loss in the intensive treatment group is unclear.
Many previous cross-sectional and longitudinal cohort studies have shown that, after age, the strongest risk factor for increased WML volume is hypertension, suggesting that treatment of hypertension might attenuate progression of WMLs.2,3 There are relatively few clinical trial reports, however, on the effects of hypertension treatment on this metric of brain structure. In a cohort study of hypertensive adults, de Leeuw et al26 reported that the successfully treated group (defined as SBP <160 mm Hg) had a slower progression of WMLs, compared with the group with poorly controlled hypertension. In the PROGRESS randomized clinical trial of a predefined antihypertensive regimen vs placebo, the treatment group had a decreased incidence of new WMLs and lesser WML volume increase.11 These studies used traditional BP treatment targets, with both having a posttreatment mean SBP greater than 130 mm Hg in the treated groups. This trial showed that intensive SBP control was associated with smaller WML volume increases compared with standard treatment targets, an association preserved in high-risk subgroups. In terms of more aggressive management of SBP, the ACCORD BP trial compared the same SBP targets as this trial in patients with diabetes and showed significantly less WML volume increase in the intensive treatment group27; however, it was not clear that this result would generalize to populations without diabetes.
While the literature documents a strong association between greater WML volumes and cognitive impairment, there is no defined threshold for WML volume associated with a clinical diagnosis of mild cognitive impairment or probable dementia, either in terms of an absolute threshold or within-person change over time. While associations between WML volume and cognitive performance are evident at the group level, there often is significant overlap comparing groups with different levels of cognitive impairment. Several studies have reported annualized rates of change for WML volume; however, populations in these studies typically differed both in terms of age and burden of vascular disease from participants in this trial.28,29 The annual rates of change for WML volume in this trial were 0.23 cm3 per year for the intensive treatment group and 0.37 cm3 per year for the standard treatment group. As expected, these rates are higher than observed in normal populations; for example, using data from the Alzheimer Disease Neuroimaging Initiative (ADNI), Carmichael et al28 reported an annual WML volume change rate of 0.08 cm3 in normal controls. The rates in this trial were more comparable to rates for participants with mild cognitive impairment and Alzheimer disease in ADNI (0.24 cm3 per year), which may in part be attributable to more comorbid vascular disease in those groups. The Rotterdam study reported an increased annual change of 0.05 cm3 per standard deviation increase in SBP (approximately 18-19 mm Hg),29 a lower change than observed in this trial. It is unclear to what extent these between-study differences reflect variability in the studied populations vs variability in technical factors such as use of multiple MRI scanners in this trial or differences in MRI acquisition and processing.
The relationship of hypertension to TBV is less robust and less well documented, although high BP generally has been associated with decreased brain volumes.30-32 Of the above-referenced hypertension treatment studies, only the ACCORD BP trial reported data on TBV, with the intensive BP treatment group also showing greater loss of TBV. In both ACCORD BP and this trial, the between-group difference was small. Jack et al33 reported TBV annual change rates of −0.4% in asymptomatic participants, increasing to −1.4% in participants with neurodegeneration from Alzheimer disease. In this trial, annualized change rates for TBV were on the order of −0.6% to −0.7% per year. It is also unclear whether the between-group difference in TBV change reflects loss of brain tissue or another factor, such as hydration status, potentially related to differences in the antihypertensive intervention.34 There was an unexpected statistical interaction between sex and intensive SBP control for change in TBV, which warrants future investigation.
This trial has several limitations. First, the duration of the intervention and follow-up was relatively short, approximately 4 years. Second, the completion rate of follow-up MRIs was lower than expected and was at least partially affected by the early termination of the intervention. Third, given the limited size of this imaging substudy and length of follow-up, informative analyses correlating changes in brain structure with the occurrence of mild cognitive impairment and dementia are not possible. However, in this substudy, the small number of participants adjudicated as having probable dementia did exhibit larger increases in WML volume and larger decreases in TBV. Fourth, generalizability to other hypertensive populations should be considered with caution, as this trial did not include persons with baseline diabetes, stroke, severe heart failure, dementia, or advanced or heavily proteinuric kidney disease or persons who resided in a nursing home. Fifth, regional WML and brain volumes were not evaluated, and it remains possible that there are differential regional associations between therapies, which will be further investigated in future analyses. Sixth, while the multisite nature of the study fosters generalization, the requisite use of different MRI scanners inevitably increased measurement variability.
Among hypertensive adults, targeting an SBP of less than 120 mm Hg, compared with less than 140 mm Hg, was significantly associated with a smaller increase in cerebral white matter lesion volume and a greater decrease in total brain volume, although the differences were small.
Corresponding Author: R. Nick Bryan, MD, PhD, Department of Diagnostic Medicine, Dell Medical School, University of Texas at Austin, 1701 Trinity St, Stop Z0300, Austin, TX 78712 (email@example.com).
Accepted for Publication: June 27, 2019.
SPRINT MIND Authors/Investigators: Ilya M. Nasrallah, MD, PhD; Nicholas M. Pajewski, PhD; Alexander P. Auchus, MD; Gordon Chelune, PhD; Alfred K. Cheung, MD; Maryjo L. Cleveland, MD; Laura H. Coker, PhD; Michael G. Crowe, PhD; William C. Cushman, MD; Jeffrey A. Cutler, MD, MPH; Christos Davatzikos, PhD; Lisa Desiderio, RT; Jimit Doshi, MS; Guray Erus, PhD; Larry J. Fine, MD; Sarah A. Gaussoin, MS; Darrin Harris; Karen C. Johnson, MD, MPH; Paul L. Kimmel, MD; Manjula Kurella Tamura, MD, MPH; Lenore J. Launer, PhD; Alan J. Lerner, MD; Cora E. Lewis, MD, MSPH; Jennifer Martindale-Adams, EdD, MS; Claudia S. Moy, PhD; Linda O. Nichols, PhD, MA; Suzanne Oparil, MD; Paula K. Ogrocki, PhD; Mahboob Rahman, MD; Stephen R. Rapp, PhD; David M. Reboussin, PhD; Michael V. Rocco, MD, MSCE; Bonnie C. Sachs, PhD; Kaycee M. Sink, MD, MAS; Carolyn H. Still, PhD, RN; Mark A. Supiano, MD; Joni K. Snyder, RN; Virginia G. Wadley, PhD; Jennifer Walker, BS; Daniel E. Weiner, MD, MS; Paul K. Whelton, MD; Valerie M. Wilson, MD; Nancy Woolard; Jackson T. Wright Jr, MD, PhD; Clinton B. Wright, MD, MS; Jeff D. Williamson, MD, MHS; R. Nick Bryan, MD, PhD.
Affiliations of SPRINT MIND Authors/Investigators: Department of Radiology, University of Pennsylvania, Philadelphia (Nasrallah, Davatzikos, Desiderio, Doshi, Erus, Bryan); Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina (Pajewski, Gaussoin, Harris, Reboussin); Department of Neurology, University of Mississippi Medical Center, Jackson (Auchus); Department of Neurology, University of Utah School of Medicine, Salt Lake City (Chelune); Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City (Cheung); Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina (Cleveland, Sink, Walker, Wilson, Woolard, Williamson); Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina (Coker); Department of Psychology, University of Alabama at Birmingham (Crowe); Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee (Cushman, Nichols); Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Cutler, Snyder); Clinical Applications and Prevention Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Fine); Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis (Johnson, Martindale-Adams); Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, Maryland (Kimmel); Division of Nephrology, Stanford University School of Medicine, Palo Alto, California (Kurella Tamura); Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland (Launer); Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio (Lerner, Ogrocki); Department of Epidemiology, University of Alabama at Birmingham (Lewis); National Institute of Neurological Disorders and Stroke, Bethesda, Maryland (Moy, C. B. Wright); Department of Medicine, University of Alabama at Birmingham (Oparil, Wadley); Department of Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, Ohio (Rahman); Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina (Rapp); Section of Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina (Rocco); Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina (Sachs); Now with Genentech, South San Francisco, California (Sink); Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio (Still); Division of Geriatrics, University of Utah School of Medicine, Salt Lake City (Supiano); Division of Nephrology, Tufts Medical Center, Boston, Massachusetts (Weiner); Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana (Whelton); Division of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, Ohio (J. T. Wright Jr).
Author Contributions: Drs Pajewski and Nasrallah had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Nasrallah, Auchus, Cheung, Coker, Cushman, Cutler, Fine, Kimmel, Lerner, Lewis, Moy, Nichols, Sink, Still, Snyder, Weiner, Whelton, Woolard, J.T. Wright, Williamson, Bryan.
Acquisition, analysis, or interpretation of data: Nasrallah, Pajewski, Auchus, Chelune, Cheung, Cleveland, Coker, Crowe, Cushman, Davatzikos, Desiderio, Doshi, Erus, Gaussoin, Harris, Johnson, Kimmel, Kurella Tamura, Launer, Lewis, Martindale-Adams, Oparil, Ogrocki, Rahman, Rapp, Reboussin, Rocco, Sachs, Sink, Supiano, Wadley, Walker, Weiner, Wilson, J.T. Wright, C.B. Wright, Williamson, Bryan.
Drafting of the manuscript: Nasrallah, Pajewski, Coker, Harris, Kurella Tamura, Martindale-Adams, Still, Wilson, Woolard, J.T. Wright, Williamson, Bryan.
Critical revision of the manuscript for important intellectual content: Nasrallah, Pajewski, Auchus, Chelune, Cheung, Cleveland, Coker, Crowe, Cushman, Cutler, Davatzikos, Desiderio, Doshi, Erus, Fine, Gaussoin, Johnson, Kimmel, Launer, Lerner, Lewis, Moy, Nichols, Oparil, Ogrocki, Rahman, Rapp, Reboussin, Rocco, Sachs, Sink, Still, Supiano, Snyder, Wadley, Walker, Weiner, Whelton, J.T. Wright, C.B. Wright, Williamson, Bryan.
Statistical analysis: Nasrallah, Pajewski, Davatzikos, Erus, Gaussoin, Reboussin, Wilson.
Obtained funding: Cheung, Coker, Cushman, Davatzikos, Fine, Johnson, Lewis, Martindale-Adams, Nichols, Reboussin, Snyder, J.T. Wright, Williamson, Bryan.
Administrative, technical, or material support: Nasrallah, Cheung, Coker, Crowe, Cushman, Cutler, Desiderio, Harris, Johnson, Kurella Tamura, Lerner, Lewis, Reboussin, Sachs, Still, Snyder, Walker, Whelton, Woolard, J.T. Wright, C.B. Wright, Williamson, Bryan.
Supervision: Nasrallah, Pajewski, Coker, Cutler, Davatzikos, Johnson, Rahman, Sink, Still, J.T. Wright, C.B. Wright, Williamson, Bryan.
Conflict of Interest Disclosures: Dr Nasrallah reported receiving grants from the National Institutes of Health (NIH). Dr Pajewski reported receiving grants from NIH. Dr Auchus reported receiving grants from NIH/National Heart, Lung, and Blood Institute (NHLBI) (contract HHSN268200900047C, subaward 000336417-041). Dr Chelune reported receiving grants from University of Utah. Dr Cheung reported receiving grants from University of Utah and Veterans Affairs Salt Lake City Healthcare System. Dr Cushman reported receiving grants from NHLBI; personal fees from Sanofi; and nonfinancial support from Novartis. Dr Crowe reported receiving grants from NIH. Dr Davatzikos reported receiving grants from NIH. Dr Doshi reported receiving grants from NIH. Dr Erus reported receiving grants from the National Institute on Aging. Ms Gaussoin reported receiving other from NIH/NHLBI. Dr Johnson reported receiving grants from NHLBI. Dr Kimmel reported receiving royalties from Elsevier. Dr Lewis reported receiving grants from NIH. Dr Oparil reported receiving grants and nonfinancial support from NIH/NHLBI; personal fees from Actelion Clinical Research, Novo Nordisk, 98point6, George Clinical Pty Ltd/Actelion/Idorsia Pharmaceuticals, Pfizer, and ROX Medical; grants from George Clinical Pty Ltd/Actelion/Idorsia Pharmaceuticals, ROX Medical, Bayer, Idorsia Pharmaceuticals, and Novartis; and serving as editor in chief of Current Hypertension Reports. Dr Rahman reported receiving grants from NIH, Bayer, and Duke Clinical Research Institute. Dr Reboussin reported receiving grants from NIH. Dr Rocco reported receiving grants from NIH, Bayer, Boehringer Ingelheim, and GlaxoSmithKline and receiving personal fees from Abbvie, George Clinical, Beacon Bioscience, and Baxter. Dr Sachs reported receiving grants from NIH/NHLBI (contract HHSN268200900047C). Dr Sink reported receiving grants from NIH and through her institution from Biogen and vTv Therapeutics and that she was a full-time faculty member at Wake Forest School of Medicine during the conduct of SPRINT but is now a full-time employee of Genentech, a member of the Roche Group (Genentech had no involvement in SPRINT). Dr Still reported receiving grants from Case Western Reserve University. Dr Supiano reported receiving grants from NIH. Dr Wadley reported receiving grants from NIH. Ms Walker reported receiving grants from NIH. Dr Weiner reported receiving grants from University of Utah and receiving personal fees from Janssen Biopharmaceuticals. Dr Wilson reported receiving grants from Wake Forest University. Ms Woolard reported receiving grants from NIH/NHLBI (contract HHSN268200900047C). Dr J. Wright reported receiving grants from NIH. Dr C. Wright reported receiving grants from NIH. Dr Bryan reported receiving grants from NIH, having equity in GalileoCDS Inc, and having a licensed and issued patent for a System and Method for Medical Image Analysis and Probabilistic Diagnosis. No other authors reported disclosures.
Funding/Support: The Systolic Blood Pressure Intervention Trial was funded by the NIH, including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke under contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C and interagency agreement A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. Azilsartan and chlorthalidone (combined with azilsartan) were provided by Takeda Pharmaceuticals International Inc. Computing resources were supported through 1S10OD023495-01, and additional support was provided through National Center for Advancing Translational Sciences clinical and translational science awards UL1TR000439 (awarded to Case Western Reserve University); UL1RR025755 (Ohio State University); UL1RR024134 and UL1TR000003 (University of Pennsylvania); UL1RR025771 (Boston University); UL1TR000093 (Stanford University); UL1RR025752, UL1TR000073, and UL1TR001064 (Tufts University); UL1TR000050 (University of Illinois); UL1TR000005 (University of Pittsburgh); 9U54TR000017-06 (University of Texas Southwestern Medical Center); UL1TR000105-05 (University of Utah); UL1 TR000445 (Vanderbilt University); UL1TR000075 (George Washington University); UL1 TR000002 (University of California, Davis); UL1 TR000064 (University of Florida); and UL1TR000433 (University of Michigan) and by National Institute of General Medical Sciences, Centers of Biomedical Research Excellence award NIGMS P30GM103337 (Tulane University).
Role of the Funder/Sponsor: The NIH and the US Department of Veterans Affairs had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript but not in the decision to submit the manuscript for publication. Takeda Pharmaceuticals had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Veterans Affairs, or the US government.
Meeting Presentation: Presented at the Alzheimer’s Association International Conference; July 25, 2018; Chicago, Illinois.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank Laurie M. Ryan, PhD, of the National Institute on Aging program staff, for her leadership and scientific guidance in the conduct of SPRINT. Dr Ryan received no compensation for her contributions.
Create a personal account or sign in to: